Trial Profile
NordiNet International Outcome Study-Observational Prospective Study on Patients Treated With Norditropin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Mar 2023
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Dwarfism; Growth disorders; Noonan syndrome; Short stature; Somatotropin deficiency; Turner's syndrome
- Focus Therapeutic Use
- Acronyms NordiNet IOS
- Sponsors Novo Nordisk
- 22 Mar 2023 Results of secondary analysis from NCT00960128 and NCT01009905 assessing the effectiveness and safety of Norditropin (somatropin, Novo Nordisk) with up to 10 years of follow-up in children with TS published in the Journal of Clinical Endocrinology and Metabolism
- 23 Mar 2021 Results assessing effectiveness and Safety of Early Growth Hormone Treatment in Children Born Small for Gestational Age from NordiNet IOS (NCT00960128) and ANSWER (NCT01009905) programs presented at the 103rd Annual Meeting of the Endocrine Society
- 05 Aug 2017 Results (n=172) assessing long term efficacy and safety published in the European Journal of Endocrinology.